Compare SkyWest Inc (SKYW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SkyWest Inc vs TransMedics Group Inc — how do they compare? SkyWest Inc trades at $107.89 (market cap $4.19B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: SkyWest Inc is the larger of the two by market cap, and SkyWest Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SKYW | TMDX | |
|---|---|---|
Market Cap | $4.19B | $3.10B |
Sector | Technology | Technology |
52-Week High | $123.72 | $150.42 |
52-Week Low | $78.40 | $61.99 |
Enterprise Value | $5.97B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $107.23, down 0.41% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows solid fundamentals with a P/E of 10.72 and net income margin of 9.78%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales amid company buybacks, while analyst consensus remains positive with a $109.33 price target. Cash flow improved in 2026 to a net positive $33 million from a $105 million deficit in 2025.
The outlook for SKYW is cautiously optimistic, supported by undervalued metrics and bullish analyst ratings, but risks include earnings volatility and insider selling. Investment opportunity lies in its low valuation and operational cash flow growth, though investors should monitor fuel cost pressures and competitive dynamics in the airline industry.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
